As of Apr 17
| +0.02 / +0.41%|
The 3 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +44.63% increase from the last price of 4.84.
The current consensus among 4 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.